Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base
Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia ...
Survival outcomes of secondary cancers in patients with Waldenstrom macroglobulinemia: An analysis of the SEER database
Incidence of secondary malignancies among patients with Waldenstrom macroglobulinemia: An analysis of the SEER database
Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma
Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type ...
Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance ...
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P)...
Large B-cell lymphoma arising in cardiac myxoma or intracardiac fibrinous mass: a localized lymphoma usually associated with Epstein-Barr virus?
The WHIM-like CXCR4(S338X)somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib ...
Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with ...
Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia
